查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
慢性阻塞性肺病市场:KOL的洞察
市场调查报告书
商品编码
1715909

慢性阻塞性肺病市场:KOL的洞察

KOL Insight - Chronic Obstructive Pulmonary Disease
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入分析了慢性阻塞性肺病 (COPD) 治疗的演变，重点关注固定剂量三联疗法的兴起以及 Dupixent 和 Nucala 等生物製剂的引入。它提供了有关如何将这些治疗方法纳入严重 COPD 患者的治疗方案以及最近的临床试验结果意味着什么的见解。本文也讨论了新型生物製剂对市场的影响，为医药专业人士提供了对 COPD 管理的当前趋势和未来方向的深入分析。

主要问题解答

  • 哪些因素影响美国和欧洲对 COPD 三合一疗法的接受度？
  • 三合一疗法方案在不同患者族群中如何使用？
  • 第三阶段 TRITON 试验是否会获得美国批准并在市场上取得成功？
  • Breztri/Trixeo 第 3 阶段 KRONOS 资料的临床影响为何？
  • Dupixent 在治疗 COPD 的核准有何意义？它将占据多少市场占有率？
  • Nucala 和 Fasenra 在治疗 COPD 方面的批准前景和竞争格局如何？

领导品牌

  • Breztri/Trixeo Aerosphere(Budesonide/Budesonide/gurikopiroreto)
  • torinbou(bekurometazon/Budesonide/gurikopironiumu)
  • toreji·eriputa(furuchikazonfuroeto/umekurijiniumu/Vilanterol)
  • deyupikusento(deyupirumabu)，nukara(meporizumabu)
  • Fasenra(benralizumab)，Ohtuvayre(ensifentrine)
  • itepekimabu
  • asutegorimabu
  • tozorakimabu
  • tanimirasuto
  • tezusupaia(tezeperumabu)

部分与会专家名单

    哈佛大学医学教授、美国麻萨诸塞州波士顿布莱根妇女医院主治医师
  • 美国马里兰州巴尔的摩市约翰霍普金斯医院肺部与重症医学系教授兼研究主任 美国宾州费城天普大学刘易斯卡茨医学院胸腔外科系教授
  • 西班牙巴塞隆纳 Vall d'Hebron 大学医院肺科教授兼顾问 英国曼彻斯特大学、南曼彻斯特大学医院 NHS 基金会感染、免疫和呼吸医学教授
  • 法国巴黎大学呼吸医学教授；科钦医院 APHP 中心呼吸内科主任

研究方法

《治疗趋势》报告是透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，了解主要疾病领域的当前和未来治疗前景而编写的。 KOL 是根据严格的筛选标准精心挑选出来的，包括全球声誉、临床专业知识和其在治疗领域的影响力。每次访谈都遵循精心设计的讨论指南。这些指南是与 KOL 合作开发的，并经过行业专家的同行评审，以确保问题全面且与当前市场动态相关。透过在每份报告发布后12个月的持续市场监测，我们及时提供来自 KOL 的重大新闻事件、市场变化和市场发展的更新。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药领域，为生物製药专业人士和决策者提供深入、可行的见解。我们深厚的行业知识使我们能够提供相关且有价值的见解，帮助我们的客户了解新兴趋势并有效地解决复杂的挑战。我们的报告以广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解为后盾，为您提供所需的准确性和可信度。独家采访和数据以及持续的市场监控使我们能够全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包含 KOL 洞察和定量医生调查的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策并在快速变化的行业中保持竞争力。

简介目录

This report provides an in-depth analysis of the evolving landscape of chronic obstructive pulmonary disease (COPD) treatment, highlighting the increasing use of fixed-dose triple combination therapies and the introduction of biologics like Dupixent and Nucala. Gain insights into how these therapies are being integrated into treatment regimens for severe COPD patients and the implications of recent clinical trial results. The report also discusses the impact of new biologic therapies on the market, offering a detailed analysis of current trends and future directions in COPD management for pharmaceutical professionals.

Key Questions Answered:

  • What factors influence the uptake of triple therapies for COPD in the US and Europe?
  • How are triple therapies used across different patient populations?
  • Can Trimbow's Phase III TRITON study lead to US approval and market success?
  • What is the clinical impact of Breztri/Trixeo's Phase III KRONOS data?
  • How significant is Dupixent's approval for COPD, and what market share can it capture?
  • What are the approval prospects and competitive landscape for Nucala and Fasenra in COPD treatment?

Key Brands:

  • Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate)
  • Trimbow (beclometasone/formoterol/glycopyrronium)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
  • Dupixent (dupilumab), Nucala (mepolizumab)
  • Fasenra (benralizumab), Ohtuvayre (ensifentrine)
  • itepekimab
  • astegolimab
  • tozorakimab
  • tanimilast
  • Tezspire (tezepelumab)

Partial List of Participating Experts:

  • Professor of Medicine at Harvard Medical School and attending physician at Brigham and Women's Hospital, Boston, MA, US
  • Professor of Medicine and Director of Research, Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, US
  • Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, US
  • Professor and Consultant, Department of Pneumology, University Hospital Vall d'Hebron, Barcelona, Spain
  • Professor, Division of Infection, Immunity & Respiratory Medicine, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
  • Professor of Respiratory Medicine at Paris Cite University and Head of the Department of Respiratory Medicine, Cochin Hospital, APHP Centre, Paris, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.